Fully Synthetic Carbohydrate-based Cancer Vaccine Development

Q: What types of Tumor-Associated Carbohydrate Antigens (TACAs) can you synthesize?

We can synthesize a wide range of TACAs including Gangliosides (GM2, GM3, GD2, GD3), Globol-series antigens (Globo H, SSEA-4), Blood group-related antigens (LeY, LeX), and Mucin-related antigens (Tn, TF, STn). We can also design custom analogs.

Malignantly transformed cells frequently display aberrant cell surface carbohydrates (TACAs), serving as specific targets for immunotherapy. However, natural extraction of these oligosaccharides yields heterogeneous mixtures that hinder precise vaccine development.

Creative Biolabs overcomes this limitation with our fully synthetic carbohydrate-based cancer vaccine solution. We utilize advanced de novo chemical synthesis to create structurally defined, homogeneous glycoforms. By conjugating these pure carbohydrates to immunogenic carriers or assembling them into multivalent clusters, we engineer next-generation vaccines capable of breaking immune tolerance and eliciting robust antibody responses.

Get a Quote

Overcoming Poor Immunogenicity in Glycovaccines

Developing effective carbohydrate vaccines involves navigating complex chemical and immunological hurdles that our platform is designed to resolve:

▶ Structural Heterogeneity: Natural isolation results in difficult-to-separate mixtures. Our Total Synthesis ensures single, homogeneous glycoforms for reproducible results.
▶ T-Cell Independence: Carbohydrates alone generally fail to recruit helper T cells. We employ Optimized Conjugation to carrier proteins (e.g., KLH, CRM197) to induce IgG class switching.
▶ Low Affinity: Monovalent interactions are often weak. Our Multivalent & Clustered Designs mimic the "cluster effect" on cell surfaces to enhance B-cell receptor cross-linking.
▶ Tolerance: Many TACAs are self-antigens. We incorporate xenogeneic T-helper epitopes or synthetic adjuvants (e.g., TLR agonists) into Unimolecular Constructs to break tolerance.

Consult Our Experts

Our Solutions

We provide a comprehensive "Design-to-Synthesis-to-Validation" pipeline focused on precision glyco-engineering:

De Novo Carbohydrate Synthesis

Automated and manual synthesis of complex tumor-associated carbohydrate antigens (TACAs) like Globol-H, GM2, Tn, and TF antigens with >98% purity.

Structurally Defined Glycoconjugates

Site-specific conjugation of synthetic carbohydrates to immunogenic carriers (KLH, BSA, Tetanus Toxoid) using advanced linker chemistry to preserve epitope integrity.

Multivalent Scaffold Design

Construction of unimolecular multi-antigenic vaccines using peptide backbones or dendrimers to display high-density carbohydrate clusters.

Immunological Evaluation

Preclinical assessment of anti-glycan antibody titers (IgM vs IgG), specificity profiling via glycoarrays, and functional killing assays (ADCC/CDC).

Specialized Synthetic Vaccine Formats

Creative Biolabs offers a diverse portfolio of synthetic constructs designed to maximize the immune visibility of carbohydrate antigens:

Unimolecular Monovalent Vaccines

These fully synthetic constructs consist of a single type of carbohydrate antigen covalently linked to a T-helper cell epitope (e.g., peptide) and a built-in adjuvant component. This "three-component" design ensures that all necessary immune signals are delivered to the same cell, enhancing uptake and presentation.

Learn More →

Custom TACA Synthesis & Library

We provide off-the-shelf and custom synthesis of difficult-to-isolate Tumor-Associated Carbohydrate Antigens. Our library includes Gangliosides (GM2, GM3, GD2, GD3), Globol-series (Globo H, SSEA-4), and Mucin-related antigens (Tn, TF, STn) with defined linker modifications.

Learn More →

Carrier Protein Conjugation Services

Overcome the T-cell independent nature of carbohydrates by coupling them to immunogenic carriers. We offer conjugation to standard proteins (KLH, CRM197, DT, BSA) and novel synthetic peptide carriers, utilizing precise stoichiometric control to prevent epitope masking.

Learn More →

Multicomponent Clustered Vaccines

Since tumors are heterogeneous, targeting a single antigen can lead to escape. We design multicomponent vaccines incorporating multiple different TACAs on a single scaffold (e.g., unimolecular pentavalent constructs) to induce a broad-spectrum immune response against diverse tumor clones.

Learn More →

Glycan Microarray & Profiling

Precise characterization of vaccine-induced antibodies is critical. We use high-throughput glycan microarrays to screen serum samples for binding specificity, ensuring the induced antibodies cross-react with tumor cells but not healthy tissue glycans.

Learn More →

Streamlined Development Workflow

Our integrated pipeline accelerates the development of defined synthetic vaccines from computational design to in vivo validation:

Step 1: Antigen Selection & Design

Service: Selection of target TACAs (e.g., Globo H, STn) based on tumor type. Design of the vaccine construct, including selection of the carrier protein (KLH/CRM197) and the conjugation linker strategy to maximize epitope exposure.

Step 2: Chemical Synthesis of Oligosaccharides

Service: De novo chemical synthesis of the selected carbohydrate antigen with a functionalized linker (e.g., thiol or amine). We utilize automated glycan assembly and traditional solution-phase synthesis to achieve high purity (>98%).

Step 3: Conjugation & Purification

Service: Controlled conjugation of the synthetic glycan to the carrier protein or multivalent scaffold. Purification via SEC or dialysis to remove unconjugated haptens. Determining the hapten-loading ratio via MALDI-TOF MS.

Step 4: Structural Characterization

Service: Rigorous physicochemical analysis including NMR spectroscopy for structural verification, mass spectrometry for molecular weight confirmation, and HPLC for purity assessment to ensure batch consistency.

Step 5: Preclinical Immunogenicity Study

Service: Immunization of mice models. Evaluation of serum antibody titers (ELISA), isotype class switching (IgM to IgG), and binding to tumor cell lines (FACS). Assessment of Complement-Dependent Cytotoxicity (CDC).

Note: This workflow is strictly for preclinical research and development purposes.

Start Your Project

Advanced Technology Platforms

Our synthetic vaccine solutions are powered by cutting-edge chemistry and immunological platforms:

Proprietary Automated Glycan Assembly (AGA) technology allowing for the rapid synthesis of complex oligosaccharides. This platform reduces synthesis time from months to days and ensures access to rare TACA structures not available from natural sources.

Automated solid-phase synthesis
Access to >50 unique building blocks
High reproducibility and purity

Versatile conjugation chemistries including thiol-maleimide, squarate, and click chemistry (CuAAC). We optimize linker length and flexibility to prevent steric hindrance and maximize B-cell receptor recognition.

Site-selective conjugation
Control over hapten-carrier ratios
Diverse linker library (PEG, Alkyl)

Construction of unimolecular multi-antigenic vaccines. This platform allows us to place different carbohydrate antigens and peptide epitopes on a single molecular scaffold, ensuring simultaneous delivery to the same Antigen Presenting Cell.

Precise molecular weight definition
Reduction of carrier-induced suppression
Enhanced potency via cluster effect

High-throughput Glycan Microarray platform containing hundreds of mammalian and tumor-associated glycans. This tool is essential for profiling the specificity of vaccine-induced antibodies and detecting potential off-target cross-reactivity.

Epitope mapping
Cross-reactivity screening
Isotype profiling (IgG vs IgM)

Automated Glycan Synthesis

Precision Conjugation

Unimolecular Scaffolds

Glycan Microarray

Inquire About Our Technology

Why Choose Creative Biolabs

Absolute Purity

Fully synthetic approach eliminates biological contaminants and batch variability found in natural extracts.

Defined Structure

Precise knowledge of antigen structure and conjugation sites allows for accurate SAR studies.

Novel Antigens

Access to rare or unstable TACA structures that cannot be isolated from natural sources.

Scalability

Robust chemical synthesis processes that are scalable for future development stages.

Request a Free Consultation

Frequently Asked Questions

Q: Why are synthetic carbohydrate vaccines preferred over natural extracts?

A: Natural extraction often yields heterogeneous mixtures of glycans that are difficult to characterize and purify. Synthetic vaccines provide a single, chemically defined structure, ensuring batch-to-batch consistency and allowing for precise immunological evaluation.

Q: Why is a carrier protein necessary for carbohydrate vaccines?

A: Carbohydrates are typically T-cell independent antigens, meaning they only induce short-lived IgM antibodies without memory. Conjugating them to a carrier protein (like KLH or CRM197) recruits T-helper cells, facilitating isotype switching to high-affinity IgG antibodies and immunological memory.

Q: What types of tumor-associated carbohydrate antigens (TACAs) can you synthesize?

A: We can synthesize a wide range of TACAs including gangliosides (GM2, GM3, GD2, GD3), Globol-series antigens (Globo H, SSEA-4), blood group-related antigens (LeY, LeX), and mucin-related antigens (Tn, TF, STn). We can also design custom analogs.

Q: What is a "unimolecular" vaccine construct?

A: A unimolecular vaccine is a fully synthetic construct where the carbohydrate B-cell epitope, a peptide T-helper epitope, and potentially an adjuvant (like a TLR agonist) are covalently linked into one single molecule. This ensures all components are delivered to the same cell simultaneously, maximizing potency.

Q: How do you verify the structure of the final conjugate?

A: We employ a multi-step characterization process. High-resolution Mass Spectrometry (MALDI-TOF) is used to determine the molecular weight and hapten loading ratio. NMR is used to verify the glycan structure before conjugation, and gel electrophoresis/HPLC ensures purity after conjugation.

Ask Our Experts

Related Resources